8-K: FutureTech II Extends SPAC Merger Deadline to August 2026

FutureTech II Acquisition Corp. stockholders approved an extension of the deadline to complete an initial business combination until August 18, 2026.

Summary

• Stockholders of FutureTech II Acquisition Corp. (FTII) approved a Fourth Amendment to its Amended and Restated Certificate of Incorporation.
• This amendment extends the period to consummate an initial business combination for up to twelve additional one-month periods, from August 18, 2025, to August 18, 2026.
• Each one-month extension requires the sponsor, FutureTech II Partners LLC, to deposit the lesser of $25,000 or $0.033 for each outstanding public share into the Trust Account.
• The deposit is in exchange for a non-interest bearing, unsecured promissory note, payable upon business combination consummation.
• The Charter Amendment Proposal was approved by 3,925,158 shares, representing 91.5% of the common stock present at the Special Meeting held on August 14, 2025.
• In connection with the vote, 228,287 shares were tendered for redemption.
• The Company deposited $18,202.77 on August 15, 2025, to effectuate the first extension, moving the deadline from August 18, 2025, to September 18, 2025.

Sentiment

Score: 5

Explanation: The extension provides necessary time, which is a positive, but the redemptions and the need for an extension indicate ongoing challenges in securing a business combination. The sponsor's commitment is a stabilizing factor, but the overall situation remains uncertain.

Positives

• Stockholders approved the extension, providing FutureTech II with up to an additional year to complete a business combination.
• The sponsor is committed to funding the monthly extensions, indicating continued support for the SPAC's objective.
• The Charter Amendment Proposal received a high approval rate of 91.5% from shares present at the Special Meeting.

Negatives

• A significant number of shares, 228,287, were tendered for redemption, reducing the cash held in the Trust Account.
• The necessity for an extension indicates challenges in identifying and closing a suitable business combination within the original timeframe.
• The extension payments, while funded by the sponsor, are in exchange for a promissory note, which could impact the combined entity's balance sheet post-merger.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions could adversely affect the company.
• Inability to successfully or timely consummate the Business Combination, including failure to obtain required stockholder or regulatory approvals, delays, or unanticipated conditions.
• Failure to realize the anticipated benefits of the Business Combination.
• Uncertainty of projected financial information with respect to FutureTech II and Longevity (the potential target).
• Risks and costs relating to regulatory approvals and compliance applicable to Longevity's products.
• Inability of FutureTech II or Longevity to obtain sufficient working capital.
• FutureTech II's and Longevity's level of indebtedness.
• Longevity's ability to successfully and timely acquire, develop, sell, and expand its technology and products, and otherwise implement its growth strategy.
• Risks relating to FutureTech II's and Longevity's operations and business, including information technology and cybersecurity risks.
• Risks related to the loss of requisite licenses.
• Potential disruption of current plans, operations, and infrastructure of Longevity as a result of the announcement and consummation of the Business Combination.
• Risks that Longevity is unable to secure or protect its intellectual property.
• Risks that the combined company experiences difficulties managing its growth and expanding operations.
• The ability to compete with existing or new companies, which could slow the development of Longevity's products or cause downward pressure on prices, fewer customer orders, reduced margins, the inability to take advantage of new business opportunities, and the loss of market share.
• The amount of redemption requests made by FutureTech II's shareholders.
• The impact of the COVID-19 pandemic.
• The ability to successfully select, execute, or integrate future acquisitions into the business, which could result in material adverse effects to operations and financial conditions.

Future Outlook

The company anticipates that subsequent events and developments will cause its assessments to change regarding the Business Combination. While the company may elect to update forward-looking statements, it specifically disclaims any obligation to do so. The Business Combination will be submitted to shareholders for their consideration and approval at a special meeting, for which a Registration Statement including proxy statements and a prospectus has been filed with the SEC.

Management Comments

• This Current Report does not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Business Combination or any related transactions, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction.
• These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) that is approaching its initial business combination deadline without having secured a definitive merger agreement. The extension provides the SPAC with additional time to identify and complete a de-SPAC transaction, a common occurrence in the SPAC market, especially given the current challenging market conditions for new listings and mergers. The mention of 'Longevity' suggests a potential target company in the health/biotech or related technology sector, aligning with broader trends of SPACs seeking innovative growth companies.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• FutureTech II Partners LLC (the Sponsor) will deposit funds into the Trust Account for each one-month extension in exchange for a non-interest bearing, unsecured promissory note payable upon consummation of a business combination. This constitutes a related party transaction between the company and its sponsor.

Stakeholder Impact

• Shareholders who redeemed their shares received their pro-rata portion of the Trust Account. Remaining shareholders face continued uncertainty but also have the opportunity for a potential business combination. The extension payments from the sponsor, while beneficial for extending the timeline, are in exchange for a promissory note, which could impact the combined entity's balance sheet.
• The Sponsor (FutureTech II Partners LLC) is committed to providing capital for extensions, demonstrating continued investment and belief in the SPAC's ability to find a target, but also incurring costs and risks associated with these advances.

Next Steps

• FutureTech II Acquisition Corp. will continue to seek and consummate an initial business combination.
• The company will make monthly deposits into the Trust Account to extend the business combination period, as needed, until August 18, 2026, or an earlier date if a business combination is completed.
• A Registration Statement, including preliminary and definitive proxy statements, will be distributed to shareholders for their vote on the Business Combination once available and declared effective by the SEC.

Key Dates

Recommendation

The approval of the extension provides the company with necessary time to pursue a business combination, which is a positive for those who believe in the SPAC's long-term potential. However, the significant redemptions and the ongoing need for extensions indicate continued uncertainty and potential challenges in securing a desirable target. The sponsor's commitment to funding extensions is a stabilizing factor, but the investment remains speculative until a definitive business combination is announced and approved. Investors should hold to see if a viable target is identified and the merger is consummated, but new investment is not recommended given the current stage and uncertainties.

Keywords

SPAC, FutureTech II Acquisition Corp, FTII, Business Combination, Extension, Proxy Vote, Shareholder Meeting, Trust Account, Redemption, Corporate Governance, Longevity